[Cytochromes P450, drug disease and personified medicine. Part 2. Therapeutic drug monitoring as a method of monooxygenase activity assessment].
In part 2 of the review the authors consider factors, having influence on the state of monooxygenase system (MOS): cytochrome P-450 gene polymorphism, induction or inhibition of these systems under effect of drugs, crossed substance specificity of cytochrome P-450 forms. Various methodical approaches (genomic, proteomic, bioelectrical technologies, therapeutic drug monitoring) to receive full information about a profile of cytochrome P-450 for every specific person, are compared. Necessity of MOS individual features assessment for optimization of drug therapy is proved.